Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure

NCT00026169 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

69

Enrollment

NIH

Sponsor class

Conditions

Malignant Neoplasm
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: imatinib mesylate
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)